N@N

Market Maker Surveillance Report. NWPX, LIFE, PRTO, SNGX, APRI, HLSPY, Losing Stocks With Lowest Price Friction For Tuesday, D

December 13, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5693 companies with "abnormal" market making, 3414 companies with positive Friction Factors and 2693 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Northwest Pipe Company (NASDAQ:NWPX), aTyr Pharma Inc. (NASDAQ:LIFE), Proteon Therapeutics (NASDAQ:PRTO), Soligenix Inc. (OTC:SNGX), Nexmed Inc. (NASDAQ:APRI), HELIOSPECTRA AB (OTC:HLSPY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  NWPX    $-2.560   -0.14%    110,774      30.93%    138,649      38.71%    -27,875      -109    
  LIFE    $-0.850   -0.23%    268,211      35.93%    289,650      38.80%    -21,439      -252    
  PRTO    $-7.350   -0.74%    1,293,416    29.56%    1,603,257    36.65%    -309,841     -422    
  SNGX    $-0.970   -0.28%    90,872       20.02%    142,307      31.35%    -51,435      -530    
  APRI    $-0.360   -0.20%    629,991      38.46%    705,432      43.06%    -75,441      -2,096  
  HLSPY   $-1.040   -0.45%    86,570       40.78%    122,937      57.91%    -36,367      -350    

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows NWPX with a dollar loss Tuesday of $-2.56000 and a Friction Factor of -109 shares. That means that it only took 109 more shares of selling than buying to move NWPX lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Northwest Pipe Company (NASDAQ:NWPX) - Northwest Pipe Company manufactures engineered steel pipe water systems in North America. The company operates in two segments, Water Transmission and Tubular Products. The Water Transmission segment primarily produces steel pipeline systems for use in drinking water infrastructure, including large diameter, high pressure, and engineered welded steel pipe products; and pipes for piling and hydroelectric projects, wastewater treatment plants, and other applications. This segment sells its products primarily to public water agencies directly or through installation contractors. The Tubular Products segment provides smaller diameter electric resistance welded steel pipes for use in various applications, including energy, construction, agriculture, and other commercial and industrial uses. This segment markets its products through a network of direct sales force personnel. Northwest Pipe Company was founded in 1966 and is headquartered in Vancouver, Washington..

aTyr Pharma Inc. (NASDAQ:LIFE) - aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California..

Proteon Therapeutics (NASDAQ:PRTO) - PROTO MED INC.

Soligenix Inc. (OTC:SNGX) - Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases primarily in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn s disease and acute radiation enteritis. This segment also offers SGX942, a novel innate defense regulator technology that is in Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has been completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. These vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey..

Nexmed Inc. (NASDAQ:APRI) - Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company s marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV, Neopharm Scientific Limited, Elis Pharmaceuticals Limited, and Global Harvest Pharmaceutical Corporation. It also develops second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and Fispemifene, a tissue-specific selective estrogen receptor modulator that is in Phase IIb clinical trial to treat secondary hypogonadism, lower urinary tract symptoms, and chronic prostatitis in men. In addition, the company plans to initiate a Phase IIb trial for RayVa to treat Raynaud s phenomenon associated with scleroderma; and develops Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. It operates in Latin America, Europe, and internationally. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California..

HELIOSPECTRA AB (OTC:HLSPY) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---